Addressing unmet needs in the treatment of COPD.

Abstract

The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.

• Authors: Francesco Patalano, Donald Banerji, Peter D'Andrea, Robert Fogel, Pablo Altman, Paul Colthorpe
• Journal: European respiratory review : an official journal of the European Respiratory Society (Eur Respir Rev) Vol. 23 Issue 133 Pg. 333-44 (Sep 2014) ISSN: 1600-0617 [Electronic] England
• PMID: 25176969 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: ©ERS 2014.

Chemical References

• Bronchodilator Agents

Topics

• Asthma (diagnosis)
• Bronchodilator Agents (therapeutic use)
• Diagnosis, Differential
• Humans
• Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy, therapy)